Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: HER2-positive Breast Cancer Clear all

Terminated Phase 3 Interventional Results available

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

NCT02340221

View directory record Official record

Conditions: Breast Cancer
Interventions: Taselisib, Placebo, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 16
States / cities: Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more

Source: ClinicalTrials.gov public record

Updated Jul 11, 2022 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1Phase 2 Interventional

Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

NCT00095706

View directory record Official record

Conditions: Breast Cancer
Interventions: Bevacizumab (drug), Herceptin (drug); Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years to 75 Years · Female only

Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 18
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 14 more

Source: ClinicalTrials.gov public record

Updated Sep 24, 2015 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1Phase 2 Interventional

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344

View directory record Official record

Conditions: Solid Tumors, Breast Cancer
Interventions: Tanespimycin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • Tucson, Arizona • New York, New York

Source: ClinicalTrials.gov public record

Updated Nov 3, 2015 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 1Phase 2 Interventional Results available

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02154529

View directory record Official record

Conditions: HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Interventions: Tesevatinib, Trastuzumab; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: La Jolla, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 26, 2022 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Phase 2 Interventional

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

NCT03393845

View directory record Official record

Conditions: Breast Cancer
Interventions: Pembrolizumab, Fulvestrant; Drug
Lead sponsor: Nancy Chan, MD; Other
Eligibility: 18 Years and older

Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 1, 2026 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637

View directory record Official record

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 218
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 2 Interventional

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

NCT00136539

View directory record Official record

Conditions: Breast Cancer
Interventions: Herceptin, Taxol, Adriamycin, Cytoxan; Drug
Lead sponsor: Harold J. Burstein, MD, PhD; Other
Eligibility: 18 Years and older

Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Feb 17, 2013 · Synced May 21, 2026, 6:33 PM EDT

Terminated No phase listed Observational

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

NCT03786107

View directory record Official record

Conditions: Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
Interventions: Almac HER-Seq Assay; Diagnostic Test
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 1,583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Source: ClinicalTrials.gov public record

Updated May 18, 2021 · Synced May 21, 2026, 6:33 PM EDT

Recruiting Not applicable Interventional

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

NCT04968964

View directory record Official record

Conditions: Breast Cancer, Cancer of the Breast
Interventions: DiviTum® TKa assay, Study Care Plans; Device · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older

Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Source: ClinicalTrials.gov public record

Updated Jan 6, 2026 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1 Interventional

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

NCT01857193

View directory record Official record

Conditions: Breast Cancer
Interventions: ribociclib (LEE011), Exemestane, Everolimus (RAD001); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 8
States / cities: Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2021 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 1Phase 2 Interventional Results available

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

NCT01132664

View directory record Official record

Conditions: Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions: BKM120, Trastuzumab, Capecitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated Aug 16, 2016 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional Results available

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

NCT00320385

View directory record Official record

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 87
States / cities: Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more

Source: ClinicalTrials.gov public record

Updated Feb 25, 2016 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1 Interventional

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

NCT04147819

View directory record Official record

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Source: ClinicalTrials.gov public record

Updated Sep 26, 2024 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

NCT02345772

View directory record Official record

Conditions: HER2-positive Breast Cancer, ER-positive Breast Cancer
Interventions: fulvestrant 500 mg, Docetaxel, Trastuzumab (H, 8mg/kg, Pertuzumab (P, 840 mg; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Source: ClinicalTrials.gov public record

Updated Feb 19, 2018 · Synced May 21, 2026, 6:33 PM EDT

Completed No phase listed Observational

Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

NCT02670577

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Agendia; Industry
Eligibility: 18 Years and older

Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Palm Springs, California • Miami, Florida • Tampa, Florida + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 26, 2018 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Phase 2 Interventional

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328

View directory record Official record

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure; Drug · Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older

Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 97
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more

Source: ClinicalTrials.gov public record

Updated May 4, 2026 · Synced May 21, 2026, 6:33 PM EDT

Completed Early Phase 1 Interventional

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

NCT03387553

View directory record Official record

Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Source: ClinicalTrials.gov public record

Updated May 6, 2026 · Synced May 21, 2026, 6:33 PM EDT

Completed No phase listed Observational

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Feb 26, 2026 · Synced May 21, 2026, 6:33 PM EDT

Not listed Phase 2 Interventional

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

NCT03812393

View directory record Official record

Conditions: Triple Negative Breast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer
Interventions: Neratinib; Drug
Lead sponsor: West Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Germantown, Tennessee

Source: ClinicalTrials.gov public record

Updated Dec 17, 2023 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1 Interventional

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032

View directory record Official record

Conditions: Breast Cancer
Interventions: Gedatolisib, Palbociclib, Letrozole, Fulvestrant; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more

Source: ClinicalTrials.gov public record

Updated Jul 26, 2022 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 3 Interventional Results available

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592

View directory record Official record

Conditions: Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions: niraparib, Physician's choice; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more

Source: ClinicalTrials.gov public record

Updated Nov 14, 2022 · Synced May 21, 2026, 6:33 PM EDT

Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Oct 3, 2024 · Synced May 21, 2026, 6:33 PM EDT

Recruiting Phase 3 Interventional

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807

View directory record Official record

Conditions: Breast Neoplasms
Interventions: Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin, Trastuzumab deruxtecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 33
States / cities: Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 26 more

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 2 Interventional Results available

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292

View directory record Official record

Conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions: Onapristone, Fulvestrant; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Source: ClinicalTrials.gov public record

Updated May 2, 2024 · Synced May 21, 2026, 6:33 PM EDT